- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02266940
Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets
December 20, 2018 updated by: Daiichi Sankyo, Inc.
A Phase 1, Open Label, Randomised, Single Dose, Three Way Crossover Study to Explore the Relative Bioavailability of DS 1971a Given as a 200 mg Tablet Formulation and a 200 mg Oral Suspension, and to Explore the Effects of Administration With a High Fat Meal on the Relative Bioavailability of the Tablet Formulation
This is an open label, randomised, 3 treatment, 3 period crossover study.
This study is designed to assess the relative bioavailability of DS 1971a from a tablet formulation and a reconstituted oral suspension and the effect of a high fat meal on the relative bioavailability of DS 1971a from the tablet formulation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, NW10 7EW
- Hammersmith Medicines Research Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects aged 18 to 65 years, inclusive
- Subjects must be in good general health as determined by medical history, physical examination and screening investigations, and be taking no regular medication
- A body mass index (BMI) in the range 18 to 30 kg/m^2, inclusive, and weighing between 50 and 100 kg. BMI is calculated as weight [kg]/(height [m])^2
- Female subjects must be of nonchildbearing potential as follows:
Must be postmenopausal (the last menstrual period was at least 12 months before Screening, and a follicle stimulating hormone [FSH] test at Screening confirms postmenopausal status); or Must be surgically sterile having undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy and/or bilateral tubal ligation
- Willing and able to consume a standard Food and Drug Administration (FDA) high fat meal
- Willing to comply with all study restrictions, including the use of contraception, concomitant medication, and dietary and lifestyle restrictions
- Sufficient intelligence to understand the nature of the study and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study
- Have given written consent to participate after reading the information and consent form, and after having the opportunity to discuss the study with the Investigator or his/her delegate
- Have given written consent to have his/her data entered into The Over-volunteering Prevention System (TOPS)
Exclusion Criteria:
- Clinically relevant abnormal history, physical findings, ECG findings, or laboratory values that could interfere with the objectives of the study or the safety of the subject
- Presence of or history of acute or chronic illness, including (but not limited to) liver or kidney disease, hypertension, seizures, or any known impairment of endocrine, or other specific body-organ dysfunction
- Presence or history of severe adverse reaction to any medicine
- Presence or history of malignant disease
- Acute or chronic infectious disease, including human immunodeficiency virus (HIV), hepatitis B virus (HBV) or C virus (HCV) infection
- Surgery (eg, stomach bypass) or medical condition that might affect absorption of medicines
- Significant illness within 4 weeks before the dose of study medication
- Participation in another clinical study of a new chemical entity or a prescription medicine within the previous 3 months, or unwilling to abstain from participating in other clinical studies during the study and for 3 months after receipt of their final dose of study medication
- Participation in another clinical study with DS-1971a
- Blood pressure (BP) and heart rate in semi supine position at the screening examination outside the ranges 90-140 mmHg systolic, 40-90 mmHg diastolic; heart rate 40-100 beats/min. Subjects with Stage 1 hypertension (systolic 140 160 mmHg; diastolic 90 100 mmHg) may be enrolled provided they do not have evidence of end organ damage, diabetes or a 10 year cardiovascular risk >20%
- Estimated glomerular filtration rate (eGFR) <80 mL/min/1.73m^2 or an absolute creatinine value above the upper limit of normal (ULN). eGFR will be estimated at Screening using the modification of diet in renal disease (MDRD) equation
- Abnormal ECG waveform morphology at Screening that would preclude accurate measurement of the QT interval duration
- Corrected QT interval (Fridericia's formula) (QTcF) interval duration >430 msec for men or >450 msec for women, obtained as an average from the measurements on duplicate screening ECGs
- Use of any prescription medicine or over-the-counter (OTC) medications, herbal remedies (such as St John's Wort), or food known to be strong inhibitors or strong inducers of cytochrome (CYP) enzymes (also known as CYP450 enzymes) during the 30 days before the dose of study medication; use of any other prescription or OTC medicine, including dietary supplements or herbal remedies, during the 7 days before the first dose of study medication
- Consumption of certain foods or beverages before the dose and throughout the study period
- Loss of more than 400 mL blood during the 3 months before the study, eg, as a blood donor
- Abuse of drugs or alcohol during the 2 years before the first dose of study medication, or intake of more than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for women)
- Use of tobacco products or nicotine containing products during the 3 months before the dose of trial medication
- Likely possibility that the volunteer will not cooperate with the requirements of the protocol
- Objection by General Practitioner (GP) to volunteer entering the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 200mg DS-1971a oral suspension fasted
200 mg DS 1971a given as oral suspension in fasted condition
|
DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
|
Experimental: 200 mg DS-1971a tablet fasted
single 200 mg DS 1971a oral tablet in fasted condition
|
A 200 mg DS 1971a tablet for oral administration
|
Experimental: 200 mg DS-1971a tablet fed
single 200 mg DS 1971a oral tablet given in fed condition
|
A 200 mg DS 1971a tablet for oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics profile of DS-1971a
Time Frame: 3 days from dose administration
|
Plasma concentration time data will be analysed using non compartmental methods.
The following PK parameters will be estimated: Cmax, Tmax and AUClast.
If data permit, AUC0-inf, CL/F, Vd/F and T½ will be estimated.
|
3 days from dose administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number and severity of adverse events as a measure of safety and tolerability
Time Frame: administration of first dose to 10 weeks
|
number and severity of adverse events as a measure of safety and tolerability
|
administration of first dose to 10 weeks
|
changes in clinical laboratory profile
Time Frame: administration of first dose to 10 weeks
|
haematology, biochemistry, and urinalysis
|
administration of first dose to 10 weeks
|
changes in physical exam profile
Time Frame: administration of first dose to 10 weeks
|
Physical examination profile includes; Height and weight, heart rate, blood pressure (BP), oral temperature and respiration rate, 12 lead electrocardiogram (ECG)
|
administration of first dose to 10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
January 1, 2015
Study Registration Dates
First Submitted
October 9, 2014
First Submitted That Met QC Criteria
October 16, 2014
First Posted (Estimate)
October 17, 2014
Study Record Updates
Last Update Posted (Actual)
December 24, 2018
Last Update Submitted That Met QC Criteria
December 20, 2018
Last Verified
January 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DS1971-A-E104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/.
In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants.
Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research.
This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on DS-1971a suspension
-
Daiichi Sankyo, Inc.Completed
-
Daiichi Sankyo, Inc.Completed
-
Medtronic BRCUnknownHeart FailureUnited Kingdom
-
Ludwig Institute for Cancer ResearchDaiichi Sankyo Co., Ltd.; Austin HealthCompletedMalignant Solid Tumor | Metastatic EphA2 Positive CancerAustralia
-
Daiichi Sankyo Co., Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Advanced CancerJapan, United States, Canada
-
Daiichi Sankyo Co., Ltd.CompletedAdvanced Solid Malignant TumorsJapan
-
Institut National de la Santé Et de la Recherche...Ultragenyx Pharmaceutical IncCompletedGlut1 Deficiency SyndromeFrance
-
Daiichi Sankyo, Inc.CompletedHepatic ImpairmentUnited States
-
Daiichi Sankyo Co., Ltd.Completed